SCHEMBL6323338

SCHEMBL6323338

NC(=O)c1c(-c2cccs2)noc1N

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
GAA P10253 3/20 0.50
MAPT P10636 2/20 0.50
HSD17B10 Q99714 2/20 0.50
KDM4E B2RXH2 2/20 0.50
TSHR P16473 2/20 0.50
HPGD P15428 1/20 0.50
RET P07949 2/20 0.47
TDO2 P48775 1/20 0.43
PLAU P00749 1/20 0.43
MEN1 O00255 6/20 0.43
KMT2A Q03164 6/20 0.43
HTT P42858 2/20 0.40
ALOX15 P16050 1/20 0.40
MAPK1 P28482 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
AURKA O14965 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322278 0.88 MEN1 (0.46) ALDH1A1GAAMAPTHSD17B10KDM4E
SCHEMBL6318330 0.81 CA1 (0.56) ALDH1A1GAAMAPTHSD17B10KDM4E
SCHEMBL6315713 0.78 KDM4E (0.62) ALDH1A1GAAMAPTKDM4EHPGD
SCHEMBL6314638 0.77 ALDH1A1 (0.54) ALDH1A1GAAMAPTHSD17B10KDM4E
SCHEMBL5151110 0.77 TDO2 (0.50) ALDH1A1MAPTHSD17B10KDM4EHPGD
SCHEMBL6316676 0.77 MEN1 (0.47) ALDH1A1GAAMAPTHSD17B10MEN1
SCHEMBL6316767 0.77 RAB9A (0.61) ALDH1A1GAAMAPTKDM4EHPGD
SCHEMBL6618183 0.77 ALDH1A1 (0.40) ALDH1A1GAAMAPTHSD17B10KDM4E
SCHEMBL6317017 0.76 KDM4E (0.52) ALDH1A1MAPTKDM4EHPGDKMT2A
SCHEMBL6315905 0.76 KDM4E (0.51) ALDH1A1GAAMAPTHSD17B10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 ALDH1A1 4444/4885GAA 789/4885MAPT 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.